Raymond James resumed coverage on Harmony Biosciences
$HRMY
Biotechnology: Pharmaceutical Preparations
Health Care
Raymond James resumed coverage of Harmony Biosciences with a rating of Outperform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/11/2025 | $55.00 | Buy | Deutsche Bank |
| 12/17/2024 | $75.00 | Buy | H.C. Wainwright |
| 10/10/2024 | Outperform | Raymond James | |
| 9/10/2024 | $56.00 | Buy | UBS |
| 6/21/2024 | $48.00 | Buy | Citigroup |
| 1/2/2024 | $30.00 | Neutral → Underperform | BofA Securities |
| 9/25/2023 | $40.00 → $31.00 | Neutral → Sell | Goldman |
| 9/7/2023 | $59.00 | Buy | Berenberg |
Deutsche Bank initiated coverage of Harmony Biosciences with a rating of Buy and set a new price target of $55.00
H.C. Wainwright initiated coverage of Harmony Biosciences with a rating of Buy and set a new price target of $75.00
Raymond James resumed coverage of Harmony Biosciences with a rating of Outperform
4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
3 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)
WAKIX® (pitolisant) Net Revenue of $184.7 Million for First Quarter 2025; Representing 20% Growth Year-over-Year; Reiterates Guidance of $820-$860M Net Income Grew 19% Year-over-Year, Building on Four Consecutive Years of Profitability; Increased Cash and Investments to Over $600 Million on Balance Sheet Completed Recruitment of Phase 3 Registrational Trial of ZYN002 in Fragile X Syndrome; On Track for Topline Data in Q3 BP1.15205, Potential Best in Class Orexin, Data to Be Presented at SLEEP 2025 Conference in June On Track for Initiation of Next-Generation Pitolisant-HD Phase 3 Registrational Trials in Narcolepsy & IH in Q4 Conference Call and Webcast to be Held Today at
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on May 6, 2025, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-267-6316 (domestic) or 203-518-9783 (international), and reference passcode HRMYQ125. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Biosciences is a pharmaceu
Data to be Presented at the Hot Topics in Child Neurology Podium Presentation Session at the American Academy of Neurology Annual Meeting Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the presentation of updated data from its Open-Label Extension (OLE) study (ZYN2-CL-017) evaluating the safety and effectiveness of ZYN002 in children, adolescents, and adults with Fragile X syndrome (FXS). The data showed clinically meaningful improvements in irritability-related symptoms prevalent in individuals with FXS. There are currently no U.S. Food & Drug Administration (FDA) approved treatments for FXS. The data will be shared during a podium presentation at the American Academy o
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the appointment of Ron Philip to the Company's Board of Directors. Ron Philip is the President and Chief Executive Officer of Orbital Therapeutics. Ron has 30 years of experience building companies, leading organizational growth, and guiding teams through the development, regulatory approval, and commercialization of novel therapies. Prior to Orbital, he was Chief Executive Officer of Spark Therapeutics, where he led the commercial launch of a novel gene therapy to treat an inherited form of blindness, expanded its therapeutic platform to larger disease areas, and acquired new technologies and assets through business developm
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced the appointment of Adam Zaeske as Executive Vice President and Chief Commercial Officer (CCO), effective March 31, 2025. The company's current CCO, Jeffrey Dierks, is voluntarily stepping down for personal reasons. Zaeske brings 25 years of global leadership across the pharmaceutical industry, building teams and transforming organizations in both the U.S. and Europe. He has broad functional experience spanning commercial strategy and operations, sales, marketing, market access, new product planning and finance. At Harmony, Zaeske will be responsible for leading the company's commercial organization, setting commercial strate
PLYMOUTH MEETING, Pa., Jan. 6, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that John C. Jacobs is stepping down as President and Chief Executive Officer and a member of the Board of Directors to pursue another opportunity. The Harmony Board of Directors has named Jeffrey M. Dayno, MD, Harmony's Executive Vice President and Chief Medical Officer, as interim CEO effective immediately. Jeff Aronin, Harmony's founder and Board chairman, will continue to lead the Board of Directors as well as
10-Q - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
8-K - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
DEFA14A - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)
WAKIX® (pitolisant) Net Revenue of $184.7 Million for First Quarter 2025; Representing 20% Growth Year-over-Year; Reiterates Guidance of $820-$860M Net Income Grew 19% Year-over-Year, Building on Four Consecutive Years of Profitability; Increased Cash and Investments to Over $600 Million on Balance Sheet Completed Recruitment of Phase 3 Registrational Trial of ZYN002 in Fragile X Syndrome; On Track for Topline Data in Q3 BP1.15205, Potential Best in Class Orexin, Data to Be Presented at SLEEP 2025 Conference in June On Track for Initiation of Next-Generation Pitolisant-HD Phase 3 Registrational Trials in Narcolepsy & IH in Q4 Conference Call and Webcast to be Held Today at
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on May 6, 2025, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-267-6316 (domestic) or 203-518-9783 (international), and reference passcode HRMYQ125. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Biosciences is a pharmaceu
WAKIX® (pitolisant) Net Revenue of $201.3 Million for Fourth Quarter and $714.7 Million for Full Year 2024; Representing Growth of 23% in Year-Five on the Market 2025 WAKIX Net Revenue Guidance Between $820 - $860 Million; On Track toward a Potential $1 Billion+ Opportunity Committed to Leadership in Sleep/Wake with Next Generation Pitolisant Formulations and Orexin 2 Receptor Agonist; Phase 3 Registrational Trials with Pitolisant HD in Narcolepsy and IH to Initiate in Q4 2025 Topline Data Readout from Phase 3 Registrational Trial with ZYN002 in Fragile X Syndrome On Track for Q3 2025 Pitolisant Patent Position Strengthened with Favorable Settlement of First Generic Litigation Con